| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $85.3M | — | -0.5% |
| Cost of Revenue | $53.0M | — | +2.4% |
| R&D Expense | $7.8M | — | -4.1% |
| SG&A Expense | $12.8M | — | +2.4% |
| Operating Income | -$4.5M | — | -118.8% |
| Pre-tax Income | -$5.4M | — | +3.1% |
| Income Tax | $856K | — | +154.4% |
| Net Income | -$6.2M | — | -56.5% |
| EPS (Basic) | -$0.41 | — | +75.3% |
| EPS (Diluted) | -$0.41 | — | +75.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $22.0M | -6.7% | -28.8% |
| Accounts Receivable | $55.5M | -3.0% | +9.7% |
| Current Assets | $92.4M | -4.1% | -6.7% |
| Total Assets | $400.2M | -1.8% | -5.1% |
| Current Liabilities | $133.6M | +8.7% | -0.2% |
| Long-term Debt | $36.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $12.5M | — | +37.9% |
| Capital Expenditures | $76K | — | -79.9% |
| Investing Cash Flow | -$5.9M | — | -5.0% |
| Financing Cash Flow | -$8.1M | — | -169.3% |
| Free Cash Flow | $12.4M | — | +43.1% |
| -11.5% |
| Total Liabilities | $205.5M | -0.5% | -9.7% |
| Stockholders' Equity | $105.0M | -5.8% | +880.2% |